This study highlights the prognostic and predictive value of circulating cytokines particularly IL-2, sPD-L1, and IL-23 in patients with advanced non-small cell lung cancer (NSCLC) undergoing immune checkpoint inhibitor (ICI) therapy. The gene discussed is IL2; the disease is non-small cell lung carcinoma.